Cempra's solithromycin gets Fast Track

Cempra Inc. (NASDAQ:CEMP) gained $1.92 to $38.70 on Wednesday after FDA granted Fast Track designation to IV and oral solithromycin ( CEM-101) to treat community acquired bacterial pneumonia (CABP). T...